Phase 1 Start for Nurix/Sanofi's STAT6 Degrader Pits Strong Genetic Rationale Against Major Viral Safety Questions

Nurix Receives Milestone for STAT6 Degrader's Phase 1 Initiation

Nurix Therapeutics announced it has earned a $10 million milestone payment from its collaborator, Sanofi, following the initiation of a Phase 1 first-in-human clinical trial for SAR448272/NX-3911. This oral STAT6 degrader is being developed for type 2 inflammatory diseases, including atopic dermatitis and asthma. This payment brings Nurix's total receipts under the 2019 collaboration agreement to approximately $139 million, with potential for an additional $453 million in future development, regulatory, and commercial milestones, plus potential royalties. Sanofi is solely responsible for the ongoing clinical development of the program.

• The $10 million milestone payment for the Phase 1 trial initiation of SAR448272/NX-3911 increases Nurix's total earnings from the 2019 collaboration with Sanofi to approximately $139 million. Nurix remains eligible for substantial future payments, including approximately $453 million in development, regulatory, and commercial milestones, alongside potential royalties on product sales, and retains a U.S. co-development and co-promotion option.
• SAR448272/NX-3911 is an oral STAT6 degrader, a key transcription factor in the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. These pathways drive type 2 inflammation, which is central to diseases such as atopic dermatitis and asthma, underscoring the drug's targeted approach for significant unmet needs in immunology.
• The advancement of SAR448272 into clinical development serves as a significant validation of Nurix's proprietary DEL-AI drug discovery platform, demonstrating its productivity in generating differentiated degrader medicines for immunology. This milestone reinforces Nurix's strategy to create substantial value through both its wholly-owned and partnered degrader programs, strengthening its overall immunology portfolio.

STAT6: A Key Driver of Type 2 Inflammation

Type 2 inflammation is driven by a coordinated response involving both the innate and adaptive immune systems, which together produce a signature cytokine profile. The interleukins IL-4, IL-5, and IL-13 are central to this process. IL-4 and IL-13 are considered pivotal signature cytokines, driving many pathobiologic changes in diseases like asthma and atopic dermatitis. While they share functions, such as inducing IgE synthesis and regulating eosinophil trafficking, IL-13 does not induce Th2 cell differentiation. The production of these cytokines by adaptive Th2 cells and group 2 innate lymphoid cells (ILC2s) forms the core of the Type 2 inflammatory response. Another key mediator is IL-9, a pleiotropic cytokine produced by various cells including mast cells, NKT cells, Th2, Th17, Treg, and ILC2s, though Th9 cells are considered the main source. IL-9 is primarily implicated in immune responses against parasites and the pathogenesis of allergic diseases like asthma and bronchial hyperreactivity.

The mechanisms of Type 2 inflammation manifest uniquely across different tissues and diseases. In inflammatory skin diseases such as atopic dermatitis, the pathogenesis involves the infiltration of macrophages, mast cells, and eosinophils, with keratinocytes playing a significant role. Stimulation with TNF-α and IFN-γ can increase the phosphorylation and nuclear translocation of STAT1 in keratinocytes, leading to the production of inflammatory chemokines including CCL22, CCL5, CCL17, and IL-8. This aligns with clinical observations that patients with symptomatic atopic dermatitis have an increased number of IL-4-producing T-helper lymphocytes (P=0.001). In chronic rhinosinusitis with nasal polyps (CRSwNP), the inflammation is predominantly Th2-type, involving epithelial barrier defects and eosinophilia. In eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), the pathogenesis likely involves interplay between T cells, B cells, and eosinophils, with eotaxin-3 and CCR4-related chemokines suggested to play a role in the selective recruitment of eosinophils. On a systemic level, IL-5 is thought to be a key cytokine for orchestrating interaction with the bone marrow.

Addressing Unmet Needs in Type 2 Inflammatory Diseases

While the development of targeted therapies has significantly advanced the management of Type 2 inflammatory diseases, several key challenges and limitations persist. These unmet needs impact clinical decision-making, long-term patient outcomes, and the overall optimization of care delivery across a range of conditions.

• Evidence Gaps in Treatment Selection: A lack of direct head-to-head comparative trials between different biologic agents complicates evidence-based therapy selection. This challenge is compounded by the absence of validated biomarkers to guide patient stratification and predict treatment response, making it difficult for clinicians to choose the optimal therapy from an expanding armamentarium.

• Long-Term Efficacy and Durability: The durability of response to biologic therapies is a significant concern. A notable proportion of patients experience a loss of response over time, require treatment escalation, or develop side effects, while the optimal treatment duration remains uncertain for chronic conditions like CRSwNP. Furthermore, many patients with hidradenitis suppurativa or chronic spontaneous urticaria exhibit inadequate or unsustained responses to available agents.

• Safety and Risk-Benefit Profiles: Balancing efficacy with safety remains a critical hurdle. Traditional therapies such as glucocorticoids and immunosuppressants are limited by their adverse effect profiles. Newer oral options like JAK inhibitors, while providing rapid disease control, carry black-box warnings. Additionally, a paucity of safety data on the concurrent use of multiple biologic agents limits the application of dual therapy strategies.

• Underserved Patient Populations: Current treatment paradigms inadequately address specific patient cohorts. A pressing need exists for effective therapies for patients with non-Type 2 inflammation, who often respond poorly to existing treatments. The pediatric population also has limited approved biologic options, despite promising results in clinical studies.

• Access and Practical Barriers: The high cost of biologic therapies is a primary barrier to care, though manufacturer assistance programs exist to improve access and affordability. Beyond cost, optimizing individualized therapy requires balancing numerous clinical considerations—such as patient age, comorbidities, and malignancy risk—with patient-centered preferences, including dosing frequency, route of administration, and willingness to self-inject.